suggested remit: to appraise the clinical and cost effectiveness of sotorasib within its marketing authorisation for previously treated KRAS G12C mutated non-small-cell lung cancer
Status In progress
Process STA 2018
ID number 3780

Project Team

Project lead

Email enquiries


Key events during the development of the guidance:

Date Update
08 December 2020 - 22 January 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
08 December 2020 In progress. DHSC referral received
01 April 2020 Topic has been referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance